DENVER — Despite challenges for approval and access, regenerative therapies for retinal diseases may not be far away from becoming viable treatment options, according to a panel discussion at Eyecelerator@ARVO.
Allan C. Ho, MD, who co-moderated the panel, told Healio that there are still unmet needs from a patient perspective for those with retinal degenerations, even with approved therapies for age-related macular degeneration and geographic atrophy. However, several innovations in cell therapy and optogenetics, as well as technologies including the Prima subretinal implant, show promise in